Akagera Medicines, a Rwandan biotech company has announced promising results after completing early stages of preclinical trials of an antibiotic drug for the treatment of pulmonary tuberculosis (TB).

AKAGERA Medicines, Inc. is a biotech company focused on the discovery and development of novel lipid nanoparticle formulations of antibacterial drugs and mRNA vaccines to treat tuberculosis, avian flu ...

Health officials issued a warning this week after someone at a suburban Chicago high school was diagnosed with active ...

Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination ...

Learn about the primary ways tuberculosis spreads through airborne transmission, high-risk settings, and effective prevention ...

Tuberculosis (TB) remains a global health challenge, affecting millions each year. Globally, an estimated 10.8 million people ...

As of early 2025, tuberculosis cases are increasing in the U.S. This disease causes significant lung damage and, if not ...

Sweat from a fingertip can be used to test whether tuberculosis (TB) patients are taking their medication properly. Until now, this could only be done by pricking blood. On March 24 it's World ...

The WHO reports that tuberculosis cases in children are rising globally. Experts say a rise in TB cases in Europe could mean ...